Anna Malczewska
Hammersmith Hospital
Internal medicineEndocrinologyPathologyOncologymicroRNALung cancerLungPancreasProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyProstate cancerLymph nodeStable DiseaseBlood samplingRadionuclide therapyCancer researchColorectal cancerMedicineBiomarker (medicine)Area under the curveChromogranin AGastroenterology
52Publications
12H-index
347Citations
Publications 51
Newest
#1I.M. Modlin (Yale University)
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 11 authors...
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (...
Source
#1Anna Malczewska (Hammersmith Hospital)H-Index: 12
#2Adam E Frampton (Hammersmith Hospital)H-Index: 33
Last. Andrea Frilling (Hammersmith Hospital)H-Index: 13
view all 12 authors...
Objective: To discover serum-based microRNA (miRNA) biomarkers for small bowel neuroendocrine tumors (SBNET) to help guide clinical decisions. Background: MiRNAs are small non-coding RNA molecules implicated in the initiation and progression of many cancers. MiRNAs are remarkably stable in bodily fluids, and can potentially be translated into clinically useful biomarkers. Novel biomarkers are needed in SBNET to determine disease aggressiveness, select patients for treatment, detect early recurre...
12 CitationsSource
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 7 authors...
INTRODUCTION Identification of residual disease after neuroendocrine tumor (NET) resection is critical for management. Post-surgery imaging is insensitive, expensive and current biomarkers ineffective. We evaluated whether the NETest, a multigene liquid biopsy blood biomarker, correlated with surgical resection and could predict recurrence. METHODS Multicenter evaluation of NET resections over 24 months (n=103): 47 pancreas, 26 small bowel, 26 lung, 2 appendix, 1 duodenum, 1 stomach. Surgery: R0...
1 CitationsSource
Abstract Biomarkers that are secretory monoanalyte products of GEP (gastro-entero-pancreatic) and BP (broncho-pulmonary) or lung NETs (neuroendocrine tumors) have significant limitations in clinical utility. The assessment of secretory activity provides little information in regard to tumor biology. Furthermore, ∼50% of NETs have measurable secretory products. Molecular genomic identification in blood (NETest liquid biopsy) of the regulators of tumor biology provide multianalyte, real-time asses...
1 CitationsSource
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 17 authors...
Introduction Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. Methods This was a multicenter ev...
4 CitationsSource
#1Anna Malczewska (Medical University of Silesia)H-Index: 12
#2Kjell Öberg (Uppsala University Hospital)H-Index: 116
Last. Beata Kos-Kudła (Medical University of Silesia)H-Index: 31
view all 3 authors...
Introduction The absence of a reliable, universal biomarker is a significant limitation in neuroendocrine neoplasia (NEN) management. We prospectively evaluated two CgA assays, (NEOLISA, EuroDiagnostica) and (CgA ELISA, Demeditec Diagnostics (DD)) and compared the results to the NETest. Methods NEN cohort (n = 258): pancreatic, n = 67; small intestine, n = 40; appendiceal, n = 10; rectal, n = 45; duodenal, n = 9; gastric, n = 44; lung, n = 43. Image-positive disease (IPD) (n = 123), image & hist...
2 CitationsSource
#1Irvin M. ModlinH-Index: 11
#2Mark KiddH-Index: 4
Last. Faidon-Marios LaskaratosH-Index: 7
view all 17 authors...
Source
Source
#1Anna MalczewskaH-Index: 12
Last. Beata Kos-KudłaH-Index: 31
view all 11 authors...
Source
#1Kambiz RahbarH-Index: 22
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: Neuroendocrine differentiation and the development of an aggressive phenotype are key features of castration-resistant prostate cancer (CRPC) disease. Current blood-based biomarkers cannot detect these treatment-refractory cancer variants. Aims: Evaluate the utility of the NETest, a blood-based 51-marker gene neuroendocrine detection tool, as a CRPC diagnostic and examine which functional gene clusters (hallmarks) differentiate CRPC from PCa. Methods:NETest gene identification in CRP...
Source